SEC Form 4 · accession 0001237899-15-000020
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Terifay
Officer — SVP Commercial
Period of report
Feb 23, 2015
Accepted (ET)
Feb 25, 2015 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 23, 2015 | M | 24,375 | $30.63 | A | 44,404 | D | |
| Common Stock | Feb 23, 2015 | F | 1,744 | $427.94 | D | 42,660 | D | |
| Common Stock | Feb 23, 2015 | F | 11,458 | $427.94 | D | 31,202 | D | |
| Common Stock | Feb 24, 2015 | S | 11,173 | $423.67 | D | 20,029 | D | |
| Common Stock | holding | — | — | — | 1,651 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $30.63 | Feb 23, 2015 | M | 24,375 | D | — | Dec 14, 2020 | Common Stock | 24,375 | 53,611 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.